. home.aspx



Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B

January 10, 2020 / Labiotech.eu

The French company Eyevensys has raised €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness. The Series B round was led by the Boehringer Ingelheim Venture Fund. New investors to Eyevensys in this round included the Global Health Sciences Fund and Pureos Bioventures. Chronic, non-infectious uveitis is a condition where the eye gets damaged by inflammation, and can potentially lead to blindness. Current treatments include oral steroids, which can cause side effects such as stomach ulcers and diabetes, and immunosuppressants, which can leave the immune system open to infections.